Immunogenicity of COVID-19 Vaccinations in Hematological Patients: 6-Month Follow-Up and Evaluation of a 3rd Vaccination

SIMPLE SUMMARY: Here we confirm lower humoral and cellular responses in hematological patients compared with controls and highlight the response in risk-groups such as CAR-T-cell recipients. The main risk factor for a poor humoral response was anti-CD20 therapy. CD19(+) B-cell and CD4(+) T-cell leve...

Descripción completa

Detalles Bibliográficos
Autores principales: Schubert, Lorenz, Koblischke, Maximilian, Schneider, Lisa, Porpaczy, Edit, Winkler, Florian, Jaeger, Ulrich, Blüml, Stephan, Haslacher, Helmuth, Burgmann, Heinz, Aberle, Judith H., Winkler, Stefan, Tobudic, Selma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032993/
https://www.ncbi.nlm.nih.gov/pubmed/35454867
http://dx.doi.org/10.3390/cancers14081962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032993/
https://www.ncbi.nlm.nih.gov/pubmed/35454867
http://dx.doi.org/10.3390/cancers14081962

Ejemplares similares